Minervini SEPA — 8 Parameter Audit
| Parameter | Result | Data |
|---|---|---|
|
Price above 150 & 200 DMA
Minervini SEPA · Criterion 1
|
PASS | Price ₹478 · 150 DMA ₹461 · 200 DMA ₹474 |
|
150 DMA above 200 DMA
Minervini SEPA · Criterion 2
|
FAIL | 150 DMA ₹461 vs 200 DMA ₹474 (-2.7%) |
|
200 DMA trending up ≥ 1 month
Minervini SEPA · Criterion 3
|
PASS | 200 DMA slope: +0.26% over 4 weeks |
|
50 DMA above 150 & 200 DMA
Minervini SEPA · Criterion 4
|
FAIL | 50 DMA ₹473 · 150 DMA ₹461 · 200 DMA ₹474 |
|
Price above 50 DMA
Minervini SEPA · Criterion 5
|
PASS | Price ₹478 · 50 DMA ₹473 (+1.0%) |
|
Price within 25% of 52-week high
Minervini SEPA · Criterion 6
|
PASS | ₹478 vs 52W high ₹568 (-15.8%) |
|
Price ≥ 30% above 52-week low
Minervini SEPA · Criterion 7
|
FAIL | ₹478 vs 52W low ₹401 (+19.2%) |
|
RS Rating ≥ 70
Minervini SEPA · Criterion 8
|
FAIL | RS Rating: 60 (threshold: ≥70) |
Weinstein Stage Analysis
Base Stage 2
Advance Stage 3
Top Stage 4
Decline
AGARWALEYE.NS is in Weinstein Stage 2 — the advancing phase. The 200-day moving average is trending upward, price is holding above all key moving averages, and the structure reflects institutional accumulation. This is the only stage where position traders should hold capital deployed in this instrument.
Relative Strength Rating
Structural Analysis
DR AGARWALS HEALTH CARE L is currently trading 1.0% above its 50-day moving average, with Weinstein Stage 2 confirmed by the moving average hierarchy.
The Minervini SEPA audit finds 4 of 8 parameters confirmed. The parameter(s) not confirmed: 150 DMA above 200 DMA, 50 DMA above 150 & 200 DMA, 30% above 52W low, RS Rating ≥70.
Sanjaya's Reading
Mitra, main dekh raha hoon DR AGARWALS HEALTH CARE L ko — 4 criteria poore hain aath mein se.
Weinstein Stage 2 mein hai yeh instrument. अभी नहीं मित्र.
This is a static snapshot
This audit was generated from NSE closing data on 31 July 2026. Run a live audit with real-time data, animated criteria reveals, and Sanjaya's full narration.
Run a Live Audit — Free →Free tier includes Nifty 50 stocks · Pro unlocks full NSE universe
Frequently Asked Questions
AGARWALEYE (DR AGARWALS HEALTH CARE L) currently meets 4 of 8 Minervini SEPA parameters. AGARWALEYE currently meets 4 of 8 Minervini SEPA parameters. The parameter(s) not confirmed: 150 DMA above 200 DMA, 50 DMA above 150 & 200 DMA, 30% above 52W low, RS Rating ≥70.
AGARWALEYE is currently in Weinstein Stage 2. AGARWALEYE.NS is in Weinstein Stage 2 — the advancing phase. The 200-day moving average is trending upward, price is holding above all key moving averages, and the structure reflects institutional accumulation. This is the only stage where position traders should hold capital deployed in this instrument.
The Kasauti verdict for AGARWALEYE is अभी नहीं मित्र (Does Not Pass Yet). The Kasauti verdict for AGARWALEYE.NS is अभी नहीं मित्र — Does Not Pass Yet. With 4 of 8 criteria met, the primary area to monitor is: 150 DMA above 200 DMA, 50 DMA above 150 & 200 DMA, 30% above 52W low, RS Rating ≥70. This is a structural methodology assessment only — not a recommendation to deploy or exit capital. This is a structural methodology assessment only — not a recommendation to deploy or exit capital.